Anti-Idiotypic Antibodies for GP5B83 CAR-T Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods to detect and quantify cells expressing chimeric antigen receptors (CARs) that include GP5B83, particularly for cancer immunotherapy, as current technologies lack specificity and efficiency in targeting GPRC5D-associated proteins.
Innovation Solution
Development of anti-idiotype antibodies and antigen-binding portions that specifically bind to GP5B83-containing proteins, enabling detection and quantification of CAR-T cells expressing GP5B83, which are designed to target GPRC5D, a protein associated with multiple myeloma and other cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current detection technologies are used to detect CAR-T cells expressing GP5B83, then detection can be performed, but the detection lacks specificity and efficiency in targeting GPRC5D-associated proteins
Solution Approach 1:
The patent introduces anti-idiotype antibodies as intermediary molecules that specifically recognize the idiotype region of GP5B83-containing antibodies. These anti-idiotype antibodies serve as mediators between the detection system and the target CAR-T cells, enabling highly specific and efficient detection by binding directly to the variable region of the GP5B83 antibody component of the CAR complex
Solution Approach 2:
The patent develops anti-idiotype antibodies with optimized binding parameters including high affinity (low Kd values) and specific epitope recognition. By changing the binding parameters of the detection antibodies to target the unique idiotype region rather than conserved regions, the detection system achieves both high specificity and efficiency in identifying GP5B83-expressing CAR-T cells
2Measurement precision
If anti-idiotype antibodies are developed to specifically bind GP5B83, then detection precision is improved, but cross-reactivity with other GPRC5D antibodies or CARs occurs
Solution Approach 1:
The patent applies local quality by directing the anti-idiotype antibodies to bind specifically to the variable region (idiotype) of the GP5B83 antibody rather than conserved constant regions. This localized binding approach ensures high detection precision for GP5B83-specific CAR-T cells while minimizing cross-reactivity with other GPRC5D-targeting antibodies that have different variable regions
Solution Approach 2:
The patent segments the antibody structure recognition by focusing detection on the unique variable region (VH and VL domains) rather than the entire antibody molecule. By segmenting the recognition target to only the idiotype-specific portions, the system achieves precise discrimination between different GPRC5D-targeting antibodies with different variable regions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-idiotype antibodies allow for precise detection and quantification of CAR-T cells expressing GP5B83, ensuring their therapeutic efficacy in targeting cancer cells while minimizing cross-reactivity with other GPRC5D antibodies or CARs.
Implementation Method 1
anti-idiotype antibodies and antigen-binding portions that specifically bind a GP5B83 containing protein, e.g., an antibody or antigen-binding portions thereof
Data Source
AI summary
In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a GP5B83 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include GP5B83.